The transcriptional activity of the androgen receptor (AR) is regulated by both ligand binding and post-translational modifications, including acetylation and small ubiquitin-like modifier (SUMO)ylation. Histone deacetylases (HDACs) are known to catalyze the removal of acetyl groups from both histones and non-histone proteins. In this study, we report that HDAC4 binds to and inhibits the activity of the AR. This inhibition was found to depend on the SUMOylation, instead of deacetylation, of the AR. Consistently, HDAC4 increases the level of AR SUMOylation in both whole-cell and cell-free assay systems, raising the possibility that the deacetylase may act as an E3 ligase for AR SUMOylation. Knock down of HDAC4 increases the activity of endogenous AR and androgen induction of prostate-specific antigen expression and prostate cancer cell growth, which is associated with decreased SUMOylation of the receptor. Overall, the studies identify HDAC4 as a positive regulator for AR SUMOylation, revealing a deacetylase-independent mechanism of HDAC action in prostate cancer cells.
INHIBITION OF ANDROGEN RECEPTOR ACTIVITY BY HISTONE DEACETYLASE 4 THROUGH RECEPTOR SUMOYLATION
Yonghua Yang,A. Tse,Pengfei Li,Qiuping Ma,Shengyan Xiang,S. Nicosia,E. Seto,X. Zhang,Wenlong Bai
Published 2010 in Oncogene
ABSTRACT
PUBLICATION RECORD
- Publication year
2010
- Venue
Oncogene
- Publication date
2010-12-06
- Fields of study
Biology, Medicine, Chemistry
- Identifiers
- External record
- Source metadata
Semantic Scholar, PubMed
CITATION MAP
EXTRACTION MAP
CLAIMS
- No claims are published for this paper.
CONCEPTS
- No concepts are published for this paper.
REFERENCES
Showing 1-39 of 39 references · Page 1 of 1
CITED BY
Showing 1-77 of 77 citing papers · Page 1 of 1